Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma.
TL;DR
A literature search of PubMed, Scopus, and Web of Science over the last 15 years focused on genomics, transcriptomics, spatial transcriptomics, proteomics, metabolomics, and Microbiomics, particularly studies combining multi-omics datasets with AI/machine learning.
OpenAlex 토픽 ·
Head and Neck Cancer Studies
Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
A literature search of PubMed, Scopus, and Web of Science over the last 15 years focused on genomics, transcriptomics, spatial transcriptomics, proteomics, metabolomics, and Microbiomics, particularly
APA
Josie J. Hockett, Molly E. Keller, David J. Reeves (2026). Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma.. The Annals of pharmacotherapy, 60(5), 500-511. https://doi.org/10.1177/10600280251391430
MLA
Josie J. Hockett, et al.. "Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma.." The Annals of pharmacotherapy, vol. 60, no. 5, 2026, pp. 500-511.
PMID
41321253
Abstract
[OBJECTIVE] The objective of this review is to evaluate clinical data regarding use of toripalimab and penpulimab use in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and to assess their impact on patient care.
[DATA SOURCES] A literature search of PubMed, Cochrane library, and clinicaltrials.gov was performed using , , .
[STUDY SELECTION AND DATA EXTRACTION] Inclusion was limited to English-language publications evaluating toripalimab and penpulimab for RM-NPC management.
[DATA SYNTHESIS] Toripalimab and penpulimab are the first US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors for RM-NPC. Both agents block the PD-1/PD-L1 interaction between tumor and T cells, enhancing anti-tumor immune responses. In the first-line setting, toripalimab plus chemotherapy achieved a median progression-free survival (PFS) of 21.4 months and overall response rate (ORR) of 78.8%. Penpulimab plus chemotherapy demonstrated a median PFS of 9.6 months and ORR of 68.1%. Toripalimab/chemotherapy was associated with an improved overall survival (hazard ratio [HR] = 0.63, = .008); penpulimab/chemotherapy overall survival data were not yet mature. As monotherapies, ORRs were 20.5% for toripalimab and 28.0% for penpulimab. Common adverse effects include immune-related adverse effects such as hypothyroidism and rash.Relevance to patient care and clinical practice in comparison to existing drugs:These agents offer crucial new therapeutic options for RM-NPC, previously managed primarily with chemotherapy. The data supporting toripalimab use are currently more mature; however, penpulimab may offer an alternative for patients unable to tolerate cisplatin due being studied in combination with carboplatin.
[CONCLUSION] Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.
[DATA SOURCES] A literature search of PubMed, Cochrane library, and clinicaltrials.gov was performed using , , .
[STUDY SELECTION AND DATA EXTRACTION] Inclusion was limited to English-language publications evaluating toripalimab and penpulimab for RM-NPC management.
[DATA SYNTHESIS] Toripalimab and penpulimab are the first US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors for RM-NPC. Both agents block the PD-1/PD-L1 interaction between tumor and T cells, enhancing anti-tumor immune responses. In the first-line setting, toripalimab plus chemotherapy achieved a median progression-free survival (PFS) of 21.4 months and overall response rate (ORR) of 78.8%. Penpulimab plus chemotherapy demonstrated a median PFS of 9.6 months and ORR of 68.1%. Toripalimab/chemotherapy was associated with an improved overall survival (hazard ratio [HR] = 0.63, = .008); penpulimab/chemotherapy overall survival data were not yet mature. As monotherapies, ORRs were 20.5% for toripalimab and 28.0% for penpulimab. Common adverse effects include immune-related adverse effects such as hypothyroidism and rash.Relevance to patient care and clinical practice in comparison to existing drugs:These agents offer crucial new therapeutic options for RM-NPC, previously managed primarily with chemotherapy. The data supporting toripalimab use are currently more mature; however, penpulimab may offer an alternative for patients unable to tolerate cisplatin due being studied in combination with carboplatin.
[CONCLUSION] Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.
MeSH Terms
Humans; Nasopharyngeal Carcinoma; Antibodies, Monoclonal, Humanized; Nasopharyngeal Neoplasms; Programmed Cell Death 1 Receptor; Neoplasm Recurrence, Local; Immune Checkpoint Inhibitors; Benzamides; Antineoplastic Combined Chemotherapy Protocols